Sustained durability and tolerability of etanercept in ankylosing spondylitis for 96 weeks

Annals of the Rheumatic Diseases

Volumn 64, Issue 11, 2005, Pages 1557-1562

  Davis, J C ^a   Van Der Heijde, D M ^b   Braun, J ^c   Dougados, M ^d   Cush, J ^e   Clegg, D ^f   Inman, R D ^g   Kivitz, A ^h   Zhou, L ⁱ   Solinger, A ⁱ   Tsuji, W ⁱ  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^c RHEUMAZENTRUM RUHRGEBIET   (Germany)

^d Rheumazentrum ^*  (France)

^e PRESBYTERIAN HOSPITAL OF DALLAS   (United States)

^f UNIVERSITY OF UTAH HEALTH SCIENCES CENTER   (United States)

^g TORONTO WESTERN HOSPITAL   (Canada)

^h Altoona Center for Clinical Research   (United States)

ⁱ AMGEN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ETANERCEPT;

ABDOMINAL PAIN; ADULT; ANKYLOSING SPONDYLITIS; ARTHRALGIA; ARTICLE; ASTHENIA; CLINICAL TRIAL; CONJUNCTIVITIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HEADACHE; HUMAN; HYPERTENSION; INJECTION SITE REACTION; MAJOR CLINICAL STUDY; MALE; NAUSEA; PAIN; PRIORITY JOURNAL; RASH; RHINITIS; SPINE MOBILITY; STATISTICAL ANALYSIS; TREATMENT OUTCOME; UVEITIS;

ADOLESCENT; ADULT; AGED; ANTIRHEUMATIC AGENTS; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOGLOBULIN G; INJECTIONS, SUBCUTANEOUS; MALE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIALS; RANGE OF MOTION, ARTICULAR; RECEPTORS, TUMOR NECROSIS FACTOR; SEVERITY OF ILLNESS INDEX; SPINE; SPONDYLITIS, ANKYLOSING; TREATMENT OUTCOME;

EID: 23644459274     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.2004.035105     Document Type: Article

References (16)

1. Braun J, Golder W, Bollow M, Sieper J, van der Heijde D. Imaging and scoring in ankylosing spondylitis. Clin Exp Rheumatol 2002;20:S178-84.
2. Davis JC Jr, van der Heijde D, Braun J, Dougados M, Cush J, Clegg DO, et al. Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial. Arthritis Rheum 2003;48:3230-6.
3. Cohen J. Clinical and laboratory improvement in ankylosing spondylitis after treatment with etanercept: a case report. J Clin Rheumatol 2000;6:221-4.
4. Marzo-Ortega H, McGonagle D, O'Connor P, Emery P. Efficacy of etanercept in the treatment of the entheseal pathology in resistant spondylarthropathy: a clinical and magnetic resonance imaging study. Arthritis Rheum 2001;44:2112-17.
5. Gorman JD, Sack KE, Davis JC Jr. Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha. N Engl J Med 2002;346:1349-56.
6. Brandt J, Khariouzov A, Listing J, Haibel H, Sorensen H, Grassnickel L, et al. Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis. Arthritis Rheum 2003;48:1667-75.
7. Calin A, Dijkmans BAC, Emery P, Hakala M, Kalden J, Leirisalo-Repo M, et al. Outcomes of a multicentre randomised clinical trial of etanercept to treat ankylosing spondylitis. Ann Rheum Dis 2004;63:1594-600.
8. Anderson JJ, Baron G, van der Heijde D, Felson DT, Dougados M. Ankylosing spondylitis assessment group preliminary definition of short-term improvement in ankylosing spondylitis. Arthritis Rheum 2001;44:1876-86.
9. Calin A, Garrett S, Whitelock H, Kennedy LG, O'Hea J, Mallorie P, et al. A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol 1994;21:2281-5.
10. Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 1994;21:2286-91.
11. Brandt J, Listing J, Sieper J, Rudwaleit M, van der Heijde D, Braun J. Development and preselection of criteria for short term improvement after anti-TNF{alpha} treatment in ankylosing spondylitis. Ann Rheum Dis 2004;63:1438-44.
12. Moreland L, Schiff M, Baumgartner S, Tindall E, Fleishmann R, Bulpitt K, et al. Etanercept therapy in rheumatoid arthritis: a randomized, controlled trial. Ann Intern Med 1999;130:478-86.
13. Weinblatt ME, Kremer JM, Bankhurst AD, Bulpitt KJ, Fleischmann RM, Fox RI, et al. A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999;340:253-9.
14. Mease PJ, Goffe BS, Metz J, VanderStoep A, Finck B, Burge DJ. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet 2000;356:385-90.
15. Leonardi CL, Powers JL, Matheson RT, Goffe BS, Zitnik R, Wang A, et al. Etanercept as monotherapy in patients with psoriasis. N Engl J Med 2003;349:2014-22.
16. Gottlieb AB, Matheson RT, Lowe N, Krueger GG, Kang S, Goffe BS, et al. A randomized trial of etanercept as monotherapy for psoriasis. Arch Dermatol 2003;139:1627-32.